Immunocore has appointed Dr Mohammed Dar as its new head of clinical development and chief medical officer.
Under his new role, Dr Mohammed will lead the continued clinical development of tebentafusp (IMCgp100) and other key programmes in Immunocore’s growing pipeline, as well as being responsible for clinical, operational, biostatistics and medical affairs functions across all therapeutic areas.
He has over 15 years of pharmaceutical industry experience in the field of oncology. Before joining Immunocore, Mohammed was vice president, clinical development oncology, R&D at MedImmune (AstraZeneca) and spent 10 years at GSK in roles of increasing responsibility focused on early clinical development in oncology.
Commenting on the appointment, Bahija Jallal chief executive officer of Immunocore, said: “Immunocore is approaching a crucial point in the Company’s development, with our lead product candidate, tebentafusp, moving through pivotal studies. Mohammed has a complete breadth of experience in leading clinical teams through early and late stage development. We’re delighted to have such a distinguished physician, scientist and industry leader join us as we progress tebentafusp and our other promising candidates through clinical development.”
